[{"orgOrder":0,"company":"Katana Pharmaceuticals","sponsor":"March Of Dimes","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Funding","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Psychiatry\/Psychology","graph2":"Undisclosed","graph3":"Katana Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Katana Pharmaceuticals \/ March Of Dimes","highestDevelopmentStatusID":"1","companyTruncated":"Katana Pharmaceuticals \/ March Of Dimes"}]

Find Clinical Drug Pipeline Developments & Deals by Katana Pharmaceuticals

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          IFT FIRST
                          Not Confirmed
                          IFT FIRST
                          Not Confirmed

                          Details : The current Innovative Challenge Grant allows Katana Pharmaceutical to develop a novel non-opioid treatment for neonatal abstinence syndrome (NAS).

                          Product Name : Undisclosed

                          Product Type : Undisclosed

                          Upfront Cash : Undisclosed

                          April 06, 2020

                          Lead Product(s) : Undisclosed

                          Therapeutic Area : Psychiatry/Psychology

                          Highest Development Status : Undisclosed

                          Sponsor : March Of Dimes

                          Deal Size : $1.1 million

                          Deal Type : Funding

                          blank